新型冠状病毒与肺纤维化致病机制的联系及治疗药物的研究进展

Research progress on the relationship and therapeutic drugs between COVID-2019 and the pathogenesis of pulmonary fibrosis

COVID-2019是一种感染性极强的传染病,主要影响肺部,严重患者会导致细胞因子风暴反应。肺纤维化是一种常见的间质性肺病,通常是组织自我修复反应的后遗症。文章旨在通过介绍COVID-2019的背景、SARS-COV-2病毒发病机制、细胞因子风暴反应和肺纤维化的发病机制如TGF-β、WNT、YAP/TAZ等相关通路来阐述两者之间可能存在的联系,同时总结了几种治疗新冠病毒感染导致肺纤维化的药物,结合对新型冠状病毒治疗的最新发现,探讨和总结潜在的治疗方法,以期为临床研究肺纤维化提供思路。

COVID-2019 is a highly infectious disease that mainly affects the lungs and can cause cytokine storm responses in severe patients.Pulmonary fibrosis is a common interstitial lung disease,often a sequelae of the tissue′s self-repairing response.This article aims to explain the possible relationship between COVID-2019 and SARS by introducing the background of COVID-2019,the pathogenesis of SARSCOV-2 virus,cytokine storm response and the pathogenesis of pulmonary fibrosis,such as TGF-β,WNT,YAP/TAZ and other related pathways.Meanwhile,it also summarizes several drugs for treating pulmonary fibrosis caused by COVID-2019 infection.Combined with the latest discovery of COVID-2019 therapy,it explores and summarizes the potential treatment methods,in order to provide ideas for clinical research on pulmonary fibrosis.